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Determinants of cardiorenal damage progression in normoten-
sive and never-treated hypertensive subjects.
Background. In the present longitudinal study, we attempted
to identify the determinants of cardiorenal damage progression
in normotensive subjects (<140/90 mm Hg) and patients with
never-treated essential hypertension.
Methods. Renal hemodynamics and function and cardiac
morphology were evaluated by isotopic techniques and echocar-
diography at baseline and after a median follow-up period of
5.2 years (range 3 to 13) in 30 normotensive and 33 hypertensive
subjects.
Results. The results are mean ± SD. Among normotensive
subjects at baseline, 50% became hypertensive during follow-
up. In the whole population, multivariate analysis showed that
age was the main determinant of the progression of systolic
blood pressure. The yearly change in glomerular filtration rate
(GFR) was exaggerated in hypertensive when compared to nor-
motensive subjects at baseline (−1.22 ± 2.71 vs. 0.12 ± 2.08
mL/min/year, respectively) (P = 0.033). In the whole popula-
tion, only baseline systolic blood pressure remained correlated
to the change in GFR, independently of GFR at baseline (model
r2 = 0.44) (P < 0.0001). The observed increase in albuminuria
was correlated with change in blood pressure only in hyper-
tensive subjects at baseline. Left ventricular mass (LVM) pro-
gression was significant only in men and its determinants were
basal plasma aldosterone, serum uric acid, and triglyceride and
change in systolic blood pressure (r2 = 0.71) (P < 0.0001).
Conclusion. In a population of untreated subjects, baseline
blood pressure as well as progression of blood pressure during
follow-up are the main determinants of the decline in GFR,
progression of albuminuria, and LVM.
Several longitudinal [1, 2] and cross-sectional [3–5]
studies conducted in normotensive and hypertensive
subjects have shown that age is the main determinant
of glomerular filtration rate (GFR) and effective renal
pasma flow (ERPF). In a longitudinal study conducted
in a large number of subjects, it was observed that the
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presence of hypertension at baseline enhanced the yearly
decline in creatinine clearance [1]. In addition, it was
reported that there was no decline in inulin clearance
within a follow-up period of 14 in normotensive subjects,
whereas a consistent fall was observed in treated patients
with essential hypertension [6]. In recent cross-sectional
studies, it was found that impaired glucose tolerance [7],
as well as the presence of left ventricular concentric re-
modeling or hypertrophy [5] were associated with an in-
crease in the slope of the inverse relationship between
age and GFR in subjects with never-treated essential hy-
pertension.
In the present longitudinal study conducted in a popu-
lation of normotensive and never-treated individuals with
essential hypertension and within a follow-up period of
3 to 13 years, we assessed the evolution as well as the
determinants of changes in arterial pressure, GFR, renal
hemodynamics, and cardiac geometry.
METHODS
Study population
The study population consisted in 30 normotensive
subjects (12 women and 18 men, aged 14 to 72 years)
and 33 hypertensive subjects (12 women and 21 men,
aged 16 to 62 years), including medical students, hospi-
tal employees, or subjects recruited from the outpatient
clinic of the department of medicine, where individuals
came for global health evaluation. Normotension was de-
fined as arterial pressure <140/90 mm Hg on at least
two subsequent visits. None of the subjects had ever
received antihypertensive therapy. Patients with clinical
evidence of atherosclerosis (stroke, coronary, and periph-
eral artery disease), heart failure, renal failure (serum cre-
atinine >120 lmol/L), diabetes mellitus (fasting blood
glucose >6.7 mmol/L), marked obesity [body mass
index (BMI) ≥35 kg/m2], or a history of alcohol abuse
(>5 drinks/day) were excluded. Doppler echocardiogra-
phy was used to detect valvular lesions in all patients.
Subjects were evaluated at baseline and after a me-
dian follow-up period of 5.2 years (range 3 to 13 years).
For various reasons, none of the patients included in the
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present study received antihypertensive therapy during
the follow-up period. In fact, all hypertensive patients
had voluntarily discontinued our prescribed antihyper-
tensive agents within 6 months after initiation.
Blood pressure measurements
Arterial pressure was measured every 3 minutes with
an automatic device (Model 8800) (Colin Corp., Komaki-
City, Japan) [8] and reported values are the average of at
least ten measurements following a 10-minute period of
rest in the supine position. Hypertension was defined as
systolic arterial blood pressure ≥140 mm Hg or diastolic
arterial blood pressure ≥90 mm Hg. Normotensive pa-
tients were classified as optimal (systolic blood pressure
of less than 120 mm Hg and diastolic blood pressure of
less than 80 mm Hg), normal (systolic blood pressure of
120 to 129 mm Hg or diastolic blood pressure of 80 to
84 mm Hg), or high-normal blood pressure (systolic blood
pressure of 130 to 139 mm Hg or diastolic blood pressure
of 85 to 89 mm Hg). If the systolic and diastolic blood
pressure readings belonged to different categories, the
higher of the two readings was used to assign to a blood
pressure category [9].
Determination of renal function
Patients came to the ward with two consecutive 24-
hour urine collections for the determination of sodium (as
an index of sodium intake), potassium, urea, creatinine,
and albumin excretion [urinary albumin excretion (UAE)
measured by radioimmunoassay]. To avoid interference
with the assessment of renal function, patients were re-
quested to stop any nonsteroidal anti-inflammatory drugs
or cimetidine at least 1 week before the procedure. As
previously described [10], GFR and ERPF were esti-
mated by urinary clearances of technetium-labeled di-
ethylene triaminopentaacetic acid (99mTc-DTPA) and
131I-ortho iodohippurate, respectively, using the con-
stant infusion technique and three to four timed urine
collections obtained every 30 minutes by spontaneous
voiding. Blood samples were obtained prior to clear-
ance determination for the measurement of plasma renin
activity and aldosterone concentration (radioimmunoas-
say) (CEA Sorin Kit) (France, Saclay). Measured creati-
nine clearance using 24-hour urine collection, GFR and
ERPF were normalized for a body surface area of 1.73
m2. Filtration fraction was calculated as GFR/ERPF. The
reproducibility of day-to-day measurements of GFR and
ERPF obtained in 20 subjects and expressed as coefficient
of variation was 6.4% and 6.3%, respectively.
Echocardiography
Echocardiographic assessment of left ventricular mor-
phology was performed by the same observer with an
Acuson 128 XP10 (Acuson, Mountain View, CA, USA)
with 2.5 or 3.5 MHz transducer. Technical details were
reported elsewhere [11]. Left ventricular hypertrophy
(LVH) was defined as left ventricular mass index (LVMI)
greater than 110 g/m2 in females and 127 g/m2 in males. Of
note, these cutoff values were obtained in a previous local
sample of normal subjects with blood pressure <140/90
mm Hg [11]. Concentric and eccentric LVH were defined
by the existence of increased (≥0.44) or normal relative
wall thickness (RWT), respectively. Concentric remodel-
ing was defined by the finding of normal left ventricular
mass associated with increased RWT.
Statistical analysis
SPSS for Windows, version 11.0 software (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Dif-
ferences in continuous variables between two groups
were assessed by the Student t test for parametric data
and differences in categorical data were assessed by the
chi-square analysis. Due to skewed distribution, urinary
albumin (lg/min or mg/mmol creatinine), plasma renin
activity, and plasma aldosterone were log transformed
prior to comparison of groups. The primary outcome pa-
rameters of interest were yearly changes in systolic blood
pressure, GFR, ERPF, albuminuria, and LVMI. Relation-
ships between outcome parameters and potential pre-
dictors were first examined through linear univariate
regression analysis. The following prespecified indepen-
dent baseline variables were included in all models: gen-
der, age, BMI, smoking, serum creatinine and uric acid,
cholesterol and triglycerides, GFR, ERPF, urinary urea,
sodium and albumin excretion, plasma aldosterone and
renin activity, LVMI, RWT, and blood pressure (systolic,
diastolic, mean, and pulse). Change in blood pressure dur-
ing follow-up was also tested as a predictor of changes in
GFR, ERPF, albuminuria, and LVMI. Variables that ex-
hibited significant univariate correlation with outcome
parameters were then included in a multiple stepwise re-
gression analysis. To avoid the regression to the mean
phenomenon, baseline value of renal or cardiac parame-
ters were always included in the multivariate model. Be-
cause gender is a determinant of left ventricular mass,
gender was included in the multivariate analysis on left
ventricular mass progression. Two-tailed (P < 0.05) was
considered statistically significant. Results are expressed
as mean ± SD or median (range).
RESULTS
Baseline characteristics
In “normotensive” individuals, the proportion of sub-
jects with optimal, normal and high-normal blood pres-
sure as defined by the World Health Organization
(WHO) [9] were respectively 10%, 33%, and 57%.
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Table 1. Population characteristics at baseline
All subjects Normotensive Hypertensive P valuea
Number 63 30 33
Male gender% 62 60 64 NS
Age years 40.6 ± 13.6 40.3 ± 15.2 40.9 ± 12.2 NS
Systolic blood pressure mm Hg 145 ± 19 130 ± 8 158 ± 17 <0.0001
Diastolic blood pressure mm Hg 87 ± 13 77 ± 9 96 ± 11 <0.0001
Heart rate bpm 65 ± 9 63 ± 8 66 ± 9 NS
Smokers% 25 20 30 NS
Family history of hypertension% 62 53 70 NS
Body mass index kg/m2 25.3 ± 3.9 24.5 ± 3.1 26 ± 4.4 NS
Serum creatinine lmol/L 88.6 ± 15.7 85.7 ± 13.8 91.3 ± 17.1 NS
Serum uric acid lmol/L 290 ± 66 291 ± 60 290 ± 72 NS
Fasting blood glucose mmol/L 4.48 ± 0.63 4.35 ± 0.41 4.65 ± 0.83 NS
Total cholesterol g/L 2.26 ± 0.55 2.24 ± 0.61 2.27 ± 0.5 NS
High-density lipoprotein cholesterol g/L 0.54 ± 0.18 0.52 ± 0.16 0.56 ± 0.2 NS
Triglycerides g/L 1.12 ± 0.83 0.98 ± 0.52 1.25 ± 1.03 NS
Urinary sodium mmol/24 hours 138 ± 69 136 ± 76 140 ± 64 NS
Urinary urea mmol/24 hours 376 ± 122 380 ± 102 372 ± 139 NS
Plasma renin activity ng/mL−1/hour−1 0.78 (0.14–2.4) 1.01 (0.14–2.25) 0.64 (0.14–2.4) NS
Plasma aldosterone ng/dL 13.6 (3.80–45.8) 11.2 (5.4–34.3) 15.5 (3.80–45.8) NS
NS is not significant. Values are expressed as mean ± SD or median (range).
at test normotensive vs. hypertensive.
Table 2. Left ventricular geometry and renal parameters at baseline
All subjects Normotensive Hypertensive P valuea
Left ventricular mass index g/m2 113 ± 30 103 ± 28 123 ± 29 0.0023
Relative wall thickness% 41.2 ± 9.7 38.1 ± 8.8 44.2 ± 9.8 0.032
Measured creatinine clearance mL/min/1.73 m2 94 ± 22 95 ± 20 93 ± 24 NS
Glomerular filtration rate mL/min/1.73 m2 104 ± 19 100 ± 16 107 ± 21 NS
Effective renal plasma flow mL/min/1.73 m2 455 ± 90 461 ± 88 449 ± 92 NS
Filtration fraction% 23.0 ± 3.0 22.1 ± 2.9 23.9 ± 2.9 0.017
Urinary albumin excretion lg/min 4.7 (0.8–219) 4.5 (0.8–25) 5.60 (1.20–219) 0.046
NS is not significant. Values are expressed as mean ± SD or median (range).
at test normotensive vs. hypertensive.
At baseline, age, gender, BMI, smoking, serum cre-
atinine, lipid profile, fasting blood glucose, and natri-
uresis were similar in normotensive and hypertensive
subjects (Table 1). As shown in Table 2, measured cre-
atinine clearance, GFR, and ERPF were similar in both
groups. Filtration fraction was higher in hypertensive
than normotensive subjects. UAE was slightly but signif-
icantly higher in hypertensive as compared to normoten-
sive subjects; in the 33 hypertensive patients, six had UAE
between 10 and 20 lg/min and five patients had UAE
higher than 20 lg/min (i.e., within the microalbuminuric
range). LVMI and RWT were higher in hypertensive than
normotensive subjects; and in the hypertensive group,
normal geometry was found in 35%, concentric remodel-
ing in 26%, concentric hypertrophy in 17%, and eccentric
hypertrophy in 22%.
Progression of blood pressure
As depicted in Table 3, the mean yearly progression of
blood pressure was 2.4 ± 3.7 for the systolic and 0.9 ±
1.7 mm Hg/year for the diastolic blood pressure in nor-
motensive subjects. Among the 15/30 normotensive sub-
jects who became hypertensive during follow-up, one had
optimal, two had normal, and 12 had high-normal blood
pressure at baseline. In fact, 71% of subjects with high-
normal blood pressure at baseline progressed to clinical
hypertension. Interestingly, 10 of these 15 subjects devel-
oped isolated systolic hypertension (systolic blood pres-
sure ≥140 mm Hg and diastolic blood pressure <90 mm
Hg).
In subjects who were hypertensive at baseline, the
yearly progression of blood pressure was 1.9 ± 3.2 for the
systolic and 0.5 ± 2.0 mm Hg/year for the diastolic blood
pressure; and the change in blood pressure was similar in
female and male subjects. No change in natriuresis and
BMI was observed at follow-up examination.
In the whole population, systolic blood pressure pro-
gression was directly correlated with age and the baseline
level of cholesterol and triglyceride and inversely corre-
lated with the baseline value of GFR. No relationship
with basal natriuresis and BMI was found. However, in
multiple regression analysis, only age remained directly
correlated with the progression of systolic blood pressure,
independently of the systolic blood pressure at baseline
(model r2 = 0.17) (P < 0.005) (Table 4).
Fesler et al: Determinants of cardiorenal damage progression 1977
Table 3. Mean yearly changes in blood pressure, cardiac and renal parameters during follow-up, according to the presence of hypertension
(≥140/90 mm Hg) at baseline
All subjects Normotensive Hypertensive
Change per year Change per year Change per year P valuea
Systolic blood pressure mm Hg 2.2 ± 3.4b 2.4 ± 3.7b 1.9 ± 3.2b NS
Diastolic blood pressure mm Hg 0.7 ± 1.9b 0.9 ± 1.7b 0.5 ± 2.0 NS
Left ventricular mass index g/m2 All 2.5 ± 3.7b 2.1 ± 3.2b 2.8 ± 4.1b NS
Female 1.2 ± 2.7 1.3 ± 1.9 1.0 ± 3.6 NS
Male 3.1 ± 3.9b 2.6 ± 3.8b 3.7 ± 4.2b NS
Glomerular filtration rate mL/min/1.73 m2 −0.58 ± 2.50 0.12 ± 2.08 −1.22 ± 2.71b 0.033
Effective renal plasma flow mL/min/1.73 m2 −1.28 ± 11.18 −2.17 ± 10.76 −0.48 ± 11.66 NS
Log of urinary albumin excretion lg/min 0.038 ± 0.067b 0.029 ± 0.066b 0.046 ± 0.068b NS
NS is not significant. Values are expressed as Mean ± SD.
at test normotensive vs. hypertensive; bP < 0.05 when compared to 0.
Table 4. Multivariate correlates of yearly changes in cardiac and renal parameters in the whole population
Beta coefficient Standard error t value P value
Change in systolic blood Age at baseline year 0.108 0.037 2.89 0.0062
pressure mm Hg/year
Change in glomerular filtration rate Systolic blood pressure at baseline mm Hg −0.052 0.013 −4.06 0.0001
mL/min/1.73 m2/year
Change in effective renal plasma Change in mean blood pressure mm Hg/year −1.55 0.58 −2.66 0.010
flow mL/min/1.73 m2/year
Urinary albumin excretion at baseline lg/min −7.29 3.07 −2.37 0.021
Change in urinary albumin Triglycerides at baseline g/L 0.027 0.01 2.73 0.0086
excretion log lg/min/year
Change in mean blood pressure mm Hg/year 0.007 0.003 2.1 0.04
Change in left ventricular mass Change in systolic blood pressure mm Hg/year 0.48 0.12 4.03 0.0004
index g/m2/year
Plasma aldosterone at baseline ng/dL 7.48 1.88 3.98 0.0005
Serum uric acid at baseline lmol/L 0.018 0.014 2.21 0.036
Triglycerides at baseline g/L 1.11 0.53 2.11 0.045
Progression of renal function and hemodynamics
As shown in Table 3, the decline of GFR during follow-
up was more marked in hypertensive than normoten-
sive subjects (−1.22 ± 2.71 vs. 0.12 ± 2.08 mL/min/1.73
m2/year) (P = 0.033). In univariate regression analysis
conducted in the whole population, the yearly change in
GFR was inversely correlated with basal values of sys-
tolic, mean and pulse pressure; UAE (log transformed)
and RWT. In fact, the higher the basal value of blood
pressure, UAE, and RWT, the higher the magnitude of
the decrease of GFR with time. In multivariate regression
analysis, the yearly change in GFR remained correlated
with the basal value of systolic blood pressure, but not
UAE or RWT, independently of the basal value of GFR
(model r2 = 0.44) (P < 0.0001).
In univariate analysis, the yearly change in ERPF was
inversely correlated with the baseline values of systolic
blood pressure, UAE, and LVMI and the yearly change in
mean blood pressure. In multivariate analysis, the yearly
change in ERPF remained correlated with the baseline
value of UAE and the yearly change in mean blood pres-
sure during follow-up, independently of the basal value
of ERPF (model r2 = 0.22) (P < 0.005) (Table 4). Of in-
terest, expression of GFR and ERPF per meter of height,
in order to unmask the influence of obesity [12], yielded
similar observations.
Progression of albuminuria
During follow-up, new onset microalbuminuria (UAE
≥20 lg/min) was observed in one normotensive subject
who converted to hypertension during follow-up and in
three subjects who were hypertensive at baseline. In uni-
variate analysis, progression of UAE was directly cor-
related with the yearly change in blood pressure and
baseline values of cholesterol and triglycerides. However,
the change in UAE was correlated with the change in
blood pressure in subjects who were hypertensive but not
in those who were normotensive at baseline. In multivari-
ate analysis, the yearly change in UAE was independently
correlated with the yearly change in mean blood pressure
and the basal value of triglycerides (model r2 = 0.27)
(P < 0.001).
Progression of cardiac morphology
As shown in Table 3, LVMI increased during follow-up
in the whole population; however, the increase tended to
be more sustained in men (3.14 ± 3.93 g/m2/year) as com-
pared to women (1.16 ± 2.74 g/m2/year). No difference in
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LVMI progression between normotensive and hyperten-
sive groups was observed. The yearly increase in LVMI
was directly correlated with the yearly change in blood
pressure and basal values of plasma aldosterone, uric
acid, and triglyceride concentration, and inversely cor-
related with the baseline value of high-density lipopro-
tein (HDL) cholesterol. In multivariate analysis, LVMI
progression remained correlated with baseline values of
plasma aldosterone, uric acid, and triglycerides and the
yearly change in systolic but not diastolic blood pressure,
independently of basal LVMI (model r2 = 0.71) (P <
0.0001) (Table 4).
DISCUSSION
In the present longitudinal study conducted in 63 nor-
motensive and hypertensive subjects followed during a
median period of 5.2 years (range 3 to 13 years), the
baseline value and/or the progression of blood pressure
during follow-up were the main determinants of the in-
crease in LVMI, the deterioration of renal function and
the increase in albuminuria.
As previously reported in the Framingham Heart Study
[13], it was found that a rather large proportion (71%)
of subjects with high-normal blood pressure at baseline
progressed to hypertension during follow-up. Similarly, in
a recent study conducted in a group of 162 normotensive
and hypertensive healthy adults aged 55 to 79 years, 62%
of patients with high-normal blood pressure at baseline
converted to hypertension within a follow-up period of 5
years [14]. In contrast with the later study, baseline blood
pressure was not a strong determinant of blood pressure
progression in the present study; and age emerged as the
most powerful factor of the increase in blood pressure
with time.
Although blood pressure progression was inversely
correlated with baseline GFR (the lower the value of
baseline GFR the higher the increase in blood pressure),
its influence did not remain when adjustment for age was
made, probably due to the strong relationship between
age and GFR. Interestingly, in a group of 33 normoalbu-
minuric normotensive subjects with type 1 diabetes, final
mean blood pressure was associated with age and GFR
at baseline, within a follow-up period of 8.4 years [15].
In the present study, GFR decreased by 0.58 mL/
min/1.73 m2/year in the whole population; however, this
decrease was significant only in subjects with hyperten-
sion at baseline (−1.22 vs. 0.12 mL/min/1.73 m2/year).
Thus hypertension tends to accelerate the fall of GFR
associated with aging. This is in perfect agreement with
other longitudinal studies conducted in untreated sub-
jects and using creatinine clearance as a marker of renal
function [1]. No change in GFR (inulin clearance) was
observed within a follow-up period of 14 years in nor-
motensive individuals, whereas a significant decline was
observed in hypertensive subjects adequately controlled
by drug therapy [6]. In fact, in the Multiple Risk Factor
Intervention Trial (MRFIT), progression to end-stage re-
nal disease (ESRD) within a follow-up period of 16 years
was observed in 0.67% of subjects with systolic blood
pressure between 160 and 179 mm Hg, 0.18% of subjects
with high-normal blood pressure and 0.08% of subjects
with optimal blood pressure at baseline [16].
Although the observed decrease in GFR was signif-
icantly influenced by baseline systolic blood pressure,
RWT of the left ventricle and albuminuria in univariate
analysis, the change in GFR was only influenced by base-
line systolic blood pressure independently of baseline
GFR in multivariate analysis. In a recent cross-sectional
study conducted in 645 never-treated hypertensive sub-
jects, it was reported that the age-associated decline of
GFR was enhanced by the concentric pattern of left ven-
tricular geometry [5]. In contrast to diabetes [17], no in-
fluence of albuminuria on the progression of GFR was
observed. Nevertheless, only one study has emphasized
the relationship between baseline UAE and the change
in creatinine clearance in essential hypertensive subjects
treated for 7 years [18].
Although ERPF did not change significantly during
follow-up in the whole population, multivariate analysis
revealed that baseline UAE and change in mean blood
pressure remained inversely correlated with the change
in ERPF, independently of baseline ERPF. This suggests
that renal vasoconstriction progressively developed in
subjects with high UAE at baseline and the largest in-
crease in blood pressure during follow-up.
The change in mean blood pressure and baseline
triglyceride emerged as the strongest independent deter-
minants of the change in UAE. Several studies conducted
in patients with essential hypertension have shown that
the change in UAE was highly correlated with the change
in blood pressure [19, 20]. Nevertheless, in the present
study, the influence of the change in blood pressure on
the change in UAE was present only in subjects with hy-
pertension at baseline. This is in agreement with our re-
cent report that within the “normotensive” range (<140/
90 mm Hg), no correlation between blood pressure and
UAE was observed, in contrast with the exquisite sensi-
tivity of LVMI to blood pressure [21].
A significant increase in LVMI was presently observed
in normotensive and hypertensive subjects, in the absence
of change in sodium intake [11] and BMI. However, de-
spite a similar change in blood pressure, LVMI increased
during follow-up only in male subjects, thus supporting
our finding that within the “normotensive” range, LVMI
correlates with blood pressure more strongly in men than
women [21].
Among the determinants of the change of LVMI during
follow-up were baseline values of plasma aldosterone and
serum uric acid, in addition to the change in systolic blood
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pressure. In fact, 71% of the variance of LVMI progres-
sion was explained by these three parameters. Although
a high initial aldosterone may predispose to an impor-
tant increase in LVMI in response to the rise in systemic
blood pressure, the role of aldosterone remains unclear.
In fact, a few studies have recently emphasized the fa-
vorable effects of mineralocorticoid receptor blockade
by spirolonolactone on LVMI, in the absence of change
in blood pressure, in hypertensive patients treated by
angiotensin-converting enzyme (ACE) inhibitors [22].
In the present longitudinal study, it was demonstrated
that within a follow-up period of 3 to 13 years, the change
in blood pressure was solely dependent on age, whereas
changes in GFR, UAE, and LVMI were almost exclu-
sively predicted by basal or change in blood pressure,
thus emphasizing the crucial role of blood pressure in
cardiorenal changes.
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